We examined autonomous and interleukin-2 (IL-2)-responsive growth activities of leukemic cells derived from peripheral blood, as well as several clinical manifestations, including serum lactate dehydrogenase (LDH) level, of 35 patients with adult T-cell leukemia (ATL) to determine whether these properties were related to prognosis. Growth activities were measured by [3Hl-thymidine incorporation of the cells after 24 hours' culture with or without exogenous IL-2. Both autonomous and IL-2-responsive growth activities were higher in the patients than in healthy controls and were significantly correlated with each other (P < .0001, r = .956).
(P = .0011, r = .530), but corrected calcium level, sex, white blood cell count, or age were not. These results strongly suggest that both growth activities of primary tumor cells, in addition to the serum LDH value, are prognostic determinants in ATL. We propose a new prognostic classification combining LDH values and autonomous growth activity into three groups: (1) high growth activity and high LDH; (2) high growth activity and low LDH, or low growth activity and high LDH; and (31 low growth activity and low LDH, which showed a significant relationship to survival time ( P = .0014; the median survival time for each group was 39,94, and 340 days, respectively).
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MATERIALS AND METHODS
Patients. We studied 35 patients aged 61.2 i 2.1 years (mean i SE), including 22 men and 13 women. The diagnosis of ATL was made on the basis of clinical features and hematologic characteristics:.' serum antibodies to ATLassociated antigens, and the presence of HTLV-I proviral genome in the DNA of leukemic cells (data not shown). Table I shows the profile of the patients studied. All patients had abnormal lymphocytosis, and FACS analysis showed an increased percentage of CD4' T cells (data not shown). All patients were evaluated at our institution until death. Patients who required intensive chemotherapy at diagnosis (14 of 22 with acute ATL and three of 13 with chronic ATL) were treated with VEPA (vincristine, cyclophosphamide, prednisolone, and doxorubicin)." Intensive chemotherapy was usually used when there was high growth activity, either autonomous or IL-2-responsive, of the leukemic cells. Patients who did not need intensive chemotherapy at the time of diagnosis either were not treated or received single-agent chemotherapy such as prednisolone, vincristine, or cyclophosphamide until their condition progressed to the acute phase (also known as "crisis"), at which point intensive chemotherapy was administered. The mean lactate dehydrogenase (LDH) value and autonomous and IL-2-responsive growth activities of the intensive chemotherapy group and non-intensive chemotherapy group were 7,995 Wroblewski units (WU), 4,791 degradations per minute (DPM), and 11,617 DPM and 1,9 I8 WU, 625 DPM, and I ,35 1 DPM, respectively. The survival interval was calculated from the time the diagnosis of ATL was made to the time of death.
Cell separation and autonomous growth and IL-2-responsive growth. The growth activity of leukemic cells was assayed at diagnosis in all patients. Peripheral blood mononuclear cells (PBMC) were separated from whole blood by centrifugation on LSM (ficollsodium diatrizoate; Bionetics, Kensington, MD). In most cases, more than 95% of the cells were leukemic as determined by the percentage of CD8 T cells and B-cell phenotypes (data not shown). Therefore, further purification of ATL cells was not performed in the present study. PBMC were cultured at Normal value ranges from 50 to 400.
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RESULTS

Growth activity of primary ATL cells with or without ZL-
2. Autonomous growth activity of the patients' leukemic cells ranged from 203 to 23,478 DPM, with mean of 2,649. E-2-responsive growth activity ranged from 404 to 58,979 DPM, with a mean of 6,337. In all patients, both autonomous and IL-%-responsive growth activity were higher than those of normal controls (mean 2 SD: 115 2 28 and 248 2 85 DPM, respectively). These two growth activities were significantly related to each other for leukemic cells (Fig 1) .
Prognostic determinants. Sex, age, peripheral white blood cell count, and corrected serum calcium concentration were not related to survival time (Table 2) . However, serum LDH value showed a significant relationship with survival time ( P = .0011, r = S30; Table 2 ). The median survival times of the high-LDH (2800 WU), and low-LDH (<S00 W) groups were 84 and 163 days, respectively (Table 3) . Higher pretreatment autonomous and L-2-responsive growth activities were both significantly associated with shorter survival times ( P = .0042, r = .472 and P = .0117, r = .421, respectively; Table 2 ). The median survival times of the high-and low-autonomous growth activity groups were 67 and 132 days, respectively. The median survival times of the high and low L-2-responsive growth activity groups were 74 and 140 days, respectively ( Table 3) . As mentioned earlier, there was heterogeneity in the treatments received by these patients. Thus, we analyzed the relationship between LDH, autonomous growth activity or IL-2-responsive growth activity, and survival time in patients with intensive or nonintensive chemotherapy at diagnosis. The mean autonomous growth, IL-2-responsive growth, and LDH values for the intensive chemotherapy group were 4,791 DPM, 11,619 DPM, and 7,995 WU, respectively, and for the non-intensive chemotherapy group, 625 DPM, 1,351 DPM, and 1,918 W, respectively. LDH, autonomous growth activity, and XL-2-responsive growth activity continued to show a significant relationship with survival time in both groups (Table 4) .
New prognostic class$cation. Based on the previously discussed, new classifications combining LDH values and growth activities were analyzed for relation to survival time. Patients were classified into three groups according to LDH values and autonomous growth activity: group A, high LDH and high growth; B, high LDH and low growth, or low LDH and high growth; and C, low LDH and low growth. This classification showed a significant relationship to shorter survival time (P = .0014; Fig 2A) . The median survival time for each group was 39, 94, and 340 days, respectively, with significant differences between A and B and between A and C. An analogous combination of LDH values and IL-2-responsive growth activity, groups I, 11, and 111 corresponding to groups A, B, and C, also showed a significant relationship to survival time ( P = .0120), with the median survival time for each group being 56, 89, and 352 days, respectively ( Fig 2B) . There was greater separation between groups (A to C) when autonomous growth activity was used in conjunction with LDH than when IL-2-responsive growth activity (I to 111) was used. In contrast, Shimoyama's classification7 did not show a significant relationship to survival time (Fig  3) .
DISCUSSION
ATL is difficult to study because of the range of symptoms and clinical courses among affected patient~.4-~'~"~ There are two forms of ATL: acute ATL, which is characterized by rapid clinical deterioration, and chronic ATL, which is slowly progressive and associated with prolonged survival. This simple scheme is complicated by descriptive subtyping that focuses on distinct histologic or clinical features of subgroups of ATL patients: smoldering, lymphomatous, etc.4~s37"0 Practically, the distinction between acute and chronic ATL is sometimes unclear, and for this reason Shimoyama et a17 have proposed criteria involving quantifiable markers such as lymphocyte count, percent atypical lymphocytes, prevalence of "flower" cells, serum LDH, corrected calcium concentration, and visceral involvement. However, these clinical criteria do not directly reflect malignant cell growth activity. We therefore analyzed leukemic cell growth activity as a possible prognostic indicator, and have shown that autono-ARIMA ET AL mous growth activity and IL-2-responsive growth activity of primary ATL cells are correlated inversely with survival. Based on these observations, we propose a new prognostic classification for the better management of ATL patients.
There are two major findings in the present study. First, we have shown that autonomous growth activity in ATL cells closely paralleled IL-2-responsive growth activity. In previous studies, we described several ATL patients whose primary leukemic cells proliferated in an autocrine or paracrine manner via an IL-2-dependent pathway."," Our present data suggest a general role for the IL-2/IL-2 receptor system in primary ATL cell growth, especially in acute ATL. In addition, leukemic cells from the lymph nodes of ATL patients proliferate by the same mechanism."" These results strongly suggest that autonomous growth of primary ATL cells is mediated by an autocrine IL-2-dependent pathway. However, mechanisms other than the IL-2/IL-2 receptor system cannot be excluded; IL-4I6 (and unpublished data, 1994) and IL-9 (Matsushita et al, manuscript submitted) affect the growth of ATL cells, although to a lesser extent than IL-2.
Second, the present study shows that autonomous and IL-2-responsive growth activities of ATL cells, as well as LDH, have a strong inverse correlation with survival. Patients with high autonomous and IL-2-responsive growth activity had a significant worse prognosis. The combination of serum LDH and growth activity, particularly autonomous growth activity, permits stratification into groups at high, intermediate, and low risk for death from ATL, which has improved prognostic value. Chemotherapy clearly improves survival in patients with acute ATL","; therefore, these data are not likely influenced by differences in the chemotherapy because most patients with "acute" ATL receive intensive chemotherapy and most patients with "chronic" ATL do not. Interestingly, the association of high growth activity with poorer survival was significant even when stratified for intensity of chemotherapy (Table 4) . Age, sex, white blood cell count, and corrected calcium were not prognostically significant. Hypercalcemia had been identified as a prognostic factor by Shimoyama et a17; this discrepancy might be because of more aggressive therapy for ATL and hypercakemia.
The observed relationship between growth activities and survival in ATL is consistent with the recently reported inverse association between autonomous growth activity and survival in acute myelogenous leukemia (AML).I7.'* IL-1 and GM-CSF production by AML blasts are related both to survival" and to blast cell autonomous growth activity.'" GM-CSF further protects AML cells from the effects of The present study shows that growth activity of ATL cells is significantly associated with survival comparably to serum LDH value. The basis for multiple clinical subtypes of ATL, as well as the transition from one type to another, is not clear at present." We have seen several patients who converted from chronic to acute ATL, the so-called "crisis." Interestingly, cells from these patients at the chronic stage have shown low autonomous growth activity and L-2-responsive growth activity; however, during the crisis stage, cells from these same patients exhibited high levels of autonomous and IL-2-responsive growth. A recent study showed mutation in the p53 gene in some acute ATL patients:2 suggesting that multiple changes in the expression of growthrelated cellular genes may be required for clonal expansion and leukemogenesis. Accumulated mutational activation events in growth-related cellular genes may similarly be associated with transitions between clinical phenotypes of ATL. Our data lend support to these ideas and emphasize the central role of the IL-Zrn-2 receptor axis in the pathogenesis of HTLV-I-induced leukemidymphoma.
